BioPorto in partnership awarded US$400K to test if Iloprost can improve coronavirus survival rates

The Danish company and leading hospitals in the Capital Region of Denmark will run the 12-month study to compare the efficacy of Iloprost to a placebo group of 80 patients

BioPorto -
The biomarker thrombomodulin, a marker of capillary damage, will be used to identify and enroll patients with severe capillary injury

BioPorto A/S (CPH:BIOPOR) has noted that Innovation Fund Denmark has awarded DKK 3 million (US$402,179) to test if the drug Iloprost can improve survival rates in SARS-Co-V2 infected patients in need of respiratory treatment.

The 12-month study will be conducted in a partnership between leading hospitals in the Capital Region of Denmark and the Danish diagnostics company, according to a statement Thursday.

More than half of all coronavirus patients on life support and in intensive care will not survive the disease (COVID-19). The primary cause of mortality is Adult Respiratory Distress Syndrome (ARDS). 

READ: BioPorto says proprietary NGAL test helps boost 1Q revenue by double-digits

Research by Professor Pär I Johansson from the Clinical Immunology Department at Rigshospitalet in Copenhagen said that ARDS damages the capillaries, leading to reduced blood flow and oxygen deprivation to central organs.

A team of Danish researchers has discovered that treatment with Iloprost (prostacyclin) – a drug used to treat certain kinds of pulmonary arterial hypertension – can potentially reduce damage to the capillaries and counteract ARDS to increase survival rates in COVID-19 patients. 

The research group has received the money to finance the 12-month randomized pilot study called COMBAT COVID-19 with patients suffering ARDS who are receiving respiratory therapy. The intention of the study is to compare the efficacy of Iloprost to placebo in a group of 80 patients.

The biomarker thrombomodulin, a marker of capillary damage, will be used to identify and enroll patients with severe capillary injury into the study. BioPorto has developed a thrombomodulin test.

The study will be conducted in a cooperative arrangement between BioPorto and the Clinical Immunology Department and the intensive care units at Rigshospitalet, the Hospital of North Zealand, Bispebjerg Hospital, Herlev Hospital and Hvidovre hospital – all from the Capital Region of Denmark.

In other COVID-19-related news, BioPorto separately is moving ahead with another Danish partner on co-development of a rapid test to detect the deadly virus.

BioPorto and the University of Southern Denmark are working on a test that will leverage the company’s patented Generic Rapid Assay Device (gRAD) technology to deliver results in less than 10 minutes. If successful, a test could be available in the second half of the year.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: BioPorto


Price: 0.75 USD

Market Cap: $200.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Investors urged to consider 'volatility index' to benefit from coronavirus...

Mining Capital's Alastair Ford says anybody who has recently been buying on the dips or hoping that the 'dead cat bounce' will go a bit higher is sitting out of pocket. ''There is one way investors could have made money, at least in terms of the indices themselves... it's possible to buy...

on 12/3/20

2 min read